World leading brainexpert to deliver freepublic lectureSPLIT - BRAIN RESEARCHEXPLAINEDChildhood epilepsyresearch offersnew hope forseizure controlAt the Howard Florey Institute’s 12th Kenneth MyerLecture you’ll find out about one of the biggestdiscoveries in neuroscience from a world leader inbrain research, Prof Michael Gazzaniga.Prof Gazzaniga, Director of the SAGE Center forthe Study of the Mind, University of California, isinternationally recognised for his ground-breakingstudies on the split-brain: one of the most fascinatingsyndromes in neurology.A split-brain occurs when the corpus callosumconnecting the brain’s two hemispheres is severed tosome degree. The surgical operation to produce thiscondition is rarely performed, and only as a last resortin otherwise intractable epilepsy. After the operation,split-brain patients seem to have two minds. Whatthe left hemisphere learns and thinks is completelyunknown to the right hemisphere, and vice versa.Gazzaniga and his colleagues’ split-brain studieshave shed light on language, mechanisms ofperception and attention, brain organisation, and thepotential for false memories. Perhaps most intriguinghave been their revelations on consciousness andevolution.Prof Gazzaniga’s long and distinguished careerincludes many books accessible to a lay audience,and his participation in the TV show The Brain andThe Mind has helped make information about brainfunction accessible to the public.Date: Thursday, 12 June <strong>2008</strong>Time: 6:15pm start for 6:30pmVenue: Dallas Brooks CentreEast MelbourneRegistrations are essential, as tickets will be issued.Registration options:Online: www.florey.edu.au/lecture/Email: rsvp@warnemarketing.com.auPhone: (03) 8610 6744Howard Florey InstituteScientists still do not know whatcauses epileptic seizures, butresearchers from Melbourne’s HowardFlorey Institute are one step closer tosolving this puzzle with the help of theirnewly developed genetically modifiedepileptic mouse.This is the first human geneticmutation based mouse model in theworld that mimics childhood absenceepilepsy (CAE). The mouse is nowhelping Dr Steven Petrou and his teamto understand the genesis of epilepsy,which will aid in the development ofbetter anti-seizure drugs.CAE involves brief staring spells,during which the child is not aware orresponsive. These episodes can occurone to 50 times per day and the age ofonset is usually three to 10 years.In about 30% of people, anti-epilepticdrugs do not adequately control theirseizures and many drugs have sideeffectssuch as rashes, lethargy andmemory problems.Dr Petrou said new treatmentstrategies were urgently needed to createbeneficial drugs without side-effects.“The problem with current drugs isthat they treat the symptoms, not the rootcause,” Dr Petrou said.“To develop new treatment strategieswe need to understand the genesis ofepilepsy, and this mouse model shouldprovide a window into that fundamentalprocess.“We all know seizures occur ifthe brain’s cortex goes haywire, butsomething is happening prior to thatevent to cause neurons to misfire, and wewant to understand that initial event.“Because mice grow so quickly,changes in the brain can be readily seenand measured.“In a week the mouse can go fromno seizures to seizures, so we caninvestigate what changes are occurringin that period and what is happening inthe critical time window that leads toseizures.“Initial findings suggest there is adefect in the brain’s cortex which maybe related to the beginning of seizuresin CAE but we are delving into deeperbrain structures as well,” Dr Petrou said.The inherited human gene mutationthat causes CAE was first detected byDr Petrou’s collaborator, Prof SamuelBerkovic from Austin Health. Throughgenetic manipulation, Dr Petrou hasintroduced this human mutation into themouse DNA, allowing the researchersto study a mouse version of the humancondition.The mutation itself is rare in humansbut it causes CAE, which is one of themore common forms of epilepsy.Dr Petrou said that modelling geneticepilepsies in mice will allow researchersto understand epilepsy from themolecular level all the way through tophysical behaviour.“Creating this link in the human brainis impossible due to the highly invasivemethodology required, so mouse modelsprovide us with a unique opportunityto discover mechanisms of seizuregenesis,” Dr Petrou added.Dr Steven Petrou is a Senior Research Fellow at theHoward Florey Institute and University of Melbourne,and an Honorary Research Fellow at the NeurosciencesVictoria and Brain Research Institute (Austin Health).Dr Petrou’s research was published by the prestigiousProceedings of the National Academy of Sciences.The Howard Florey is collaborating with <strong>Australia</strong>nbiotechnology company, Bionomics, to leverage thismodel for the advancement of anti-epilepsy drugdiscovery.10 THE EPILEPSY REPORT MAY <strong>2008</strong>
<strong>Epilepsy</strong> andsocial stigma:myths and realities<strong>Epilepsy</strong> is not a purely ‘neurological phenomenon’ and itrequires a juxtaposition of both the neurological and sociologicalcomponents to elucidate the ‘unexplored’ dimensions ofthis disorder. Although clinical, neurological, biological,psychiatric and even therapeutic aspects of epilepsy have beenfairly consistently reviewed, relatively little is known aboutpsychosocial aspects of this condition.From ancient to modern times,epilepsy has carried with it an‘undesirable’ amount of social stigmathat affects people with epilepsy invarying degrees in diverse culturalsettings. The father of sociologyof stigma; Goffman (1969) definesstigma as ‘an undesired difference’.He argues that the stigmatised areseen by others as ‘not quite humans’who are legitimate targets fordiscrimination. Link and Phelan (2001)define stigma contextually; that stigmaexists ‘when elements of labelling,stereotyping, separation, status loss,and discrimination occur together ina power situation that allows them’.Even in industrial nations like America,epilepsy carries a stigma that datesback to ancient civilisations. Someargue that stigma related to epilepsy isworse than the stigma of cancer or HIV/AIDS. Misunderstanding, fear, andanxiety resulting from stigma hamperscare and public recognition and resultsin social and even legal discriminationagainst those living with epilepsy. Ina WHO document ‘<strong>Epilepsy</strong>: socialconsequences and economic aspects’,some misunderstandings about epilepsyfrom around the world have beensummarised;• In Cameroon, it is believed thatpeople with epilepsy are inhabitedby the devil;• In China, epilepsy diminishes theprospects of marriage, especiallyfor women.• In some parts of India, attempts aremade to exorcise evil spirits frompeople with epilepsy by tying themto trees, bearing them, and cutting aportion of hair from their head;• In Indonesia, epilepsy is oftenconsidered as punishment fromunknown dark forces;• In Liberia, the cause of epilepsy isperceived as related to witchcraft orevil spirits;• In Nepal, epilepsy is associatedwith weakness, possession by anevil spirit;• In Swaziland, many traditionalhealers mention sorcery as thecause of epilepsy;• In Uganda, epilepsy is thought tobe contagious and so people withepilepsy are not allowed to join thecommunal food pot.Research shows that people withepilepsy in developing countriesparticularly in Africa, suffersubstantially from stigma and socialexclusion and they are more likely to beunemployed, get less educated and getless married.Fernandes et al (2007) in a recentstudy in Brazil found that the magnitudeof stigma is different within segments ofthe local society, highlighting that socioculturalfactors such as gender, religion,level of education may be importantpredictors of stigma. In a Korean studyby Lee et al, (2005) involving 400 adultswith epilepsy indicated that 31% ofthem felt stigmatised by their condition.Jaya Pinikahana PhDPrincipal Social Researcher<strong>Epilepsy</strong> Foundation of VictoriaChristine Walker PhDChief Executive Officer,Chronic Illness AllianceDilorio et al (2003) reported that peoplereporting higher levels of stigma werethose who had their first seizure beforethe age of 50. In an Estonian study,Ratsepp and his colleagues (2000) foundthat overall 55% of people with epilepsybelieved that they had been treatedunfairly at work or when trying to get ajob, 51% of respondents felt stigmatisedby epilepsy, and 14% of them highly so.Baker et al (2000) in a review on ‘stigmaof epilepsy; a European perspective’involving more than 5000 people withepilepsy in 15 countries in Europefound that 51% of respondents reportedfeeling stigmatised, with 18% reportinghighly stigmatised. Paradoxically, oneBritish study found no evidence thatstigma affects the lives of those whoseepilepsy was not complicated by otherpathologies (Britten et al, 1984).Research shows that stigma hasa negative affect on the quality ofTHE EPILEPSY REPORT MAY <strong>2008</strong>11